Current funding opportunities related to TB and HIV, expired RFAs will be hidden after closing date. Sort using the tags menu to the right.
CRDFGlobal RFP Announced: Cross Consortium Funding for the RePORT International Consortium
The RePORT International Coordinating Center (RICC) invites researchers to submit full proposals for the Cross Consortium Funding for the RePORT International Consortium. This initiative will provide a maximum of two (2) years of funding to support two (2) to three (3) projects to support the development of collaborations across the RePORT consortium. This competition is organized by the RICC and administered by CRDF Global on behalf of the National Institute of Allergies and Infectious Diseases (NIAID).
Full proposals must be submitted to CRDF Global’s Cross Consortium intake inbox Cross-Consortium@crdfglobal.org no later than Friday, June 21, 2024 (23:59) U.S. Eastern Standard Time (EST). Proposals will undergo a round of peer evaluation.
Please visit CRDF Global’s website to view the request for proposals for more information by following this link: https://www.crdfglobal.org/rfp/cross-consortium-funding-for-the-report-international-consortium/
NIAID Funding Opportunity: Brazil Regional Prospective Observational Research in Tuberculosis
Brazil Regional Prospective Observational Research in Tuberculosis (RePORT) (U01 Clinical Trial Not Allowed)
Application open date: November 08, 2021
Expiration Date: December 09, 2021
The purpose of this Funding Opportunity Announcement (FOA) is to support a Brazil-US Regional Prospective Observational Research in Tuberculosis (RePORT) network to advance TB and TB/HIV science. The RePORT Brazil network will leverage and build upon Brazilian cohorts currently following adult and pediatric populations with active TB disease and their contacts or other high TB-risk individuals to address key research questions of regional and global interest. Specific areas supported under this program include, but are not limited to, research and development projects in TB/HIV in the areas of molecular epidemiology, diagnostics, biomarkers, vaccine development, and the impact of co-morbidities such as HIV and diabetes. Research outcomes should be capable of advancing tools with public health impact or of influencing decision making in TB public health to inform stakeholders on the best practices for early prevention, diagnosis, and clinical management of TB and TB/HIV.
Click here for more information about this funding opportunity!